
















430Reduced Frequency of Regulatory T Cells in Peripheral
Blood Stem Cell Compared to Bone Marrow
Transplantations
Celine Blache,1 Joe-Marc Chauvin,1 Aude Marie-Cardine,2 Nathalie Contentin,3
Pascal Pommier,4 Ingrid Dedreux,1 Stephanie Franc¸ois,1 Serge Jacquot,1 Dominique Bastit,4
Olivier Boyer1Peripheral blood stem cell transplantation (PBSCT) is an alternative to bone marrow transplantation (BMT).
Although CD41CD251CD127lo regulatory T cells (Tregs) have been shown to play important roles in the
control of T cell reactivity, the Treg contents of both graft types have not been analyzed comparatively to
date. We report herein that Treg frequencies are significantly reduced in PBSC compared to BM transplants.
Furthermore, most Tregs from PBSC transplants are CD62Llo, a phenotype reported to have poor suppres-
sor activity. Both granulocyte-colony stimulating factor (G-CSF) administration and leukapheresis were
found to contribute to the loss of CD62L1 Tregs. Although higher T cell numbers are infused in PBSCT
than in BMT, it is possible that the reduced Treg content of PBSC transplants may represent 1 factor contrib-
uting to the higher risk of GVHD reported after PBSCT.
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Hematopoietic stem cell transplantation (HSCT) is
a common therapeutic option for different hematologic
diseases including leukemia. In addition to cord blood
(CB), the HSCTs mostly consists of bone marrow
(BM) cells or peripheral blood stem cells (PBSC) that
are recoveredby leukapheresis after granulocyte-colony
stimulating factor (G-CSF)mobilization. Both BM and
PBSC transplants (PBSCTs) contain high numbers of
mature T cells that contribute to T cell reconstitution,
favor engraftment, andmay provide an antileukemic ef-
fect, but also cause graft-versus-host disease (GVHD).1Inserm, U905, Rouen, France; University of Rouen,
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6/j.bbmt.2009.10.027CD41CD251 regulatory T cells (Treg) have
recently emerged as key players in the regulation of
immune responses, notably for preventing autoimmune
diseases [1]. Quantitative and/or qualitative Treg de-
fects have been reported in various inflammatory/auto-
immune diseases since 2004 [2,3], and there is strong
evidence that these cells also play a major role in the
control of T cell alloreactivity, including inHSC trans-
plantation. Although initial studies trying to correlate
Treg numbers and the risk of GVHD brought contro-
versial results [4], several authors have now reported
a lower cumulative incidence of GVHD in patients
receiving a PBSCT containing higher Treg numbers
[5-7] or an inverse correlation between GVHD and
Foxp3 gene expression in recipient peripheral blood
mononuclear cells (PBMCs) [8]. This is consistent
with experimental data inmice in whichTreg depletion
of HSC transplants exacerbates lethal GVHD, whereas
Treg supplementation is protective [9,10]. Hence, ex
vivo expanded Tregs have been proposed as a strategy
to modulate GVHD after HSC transplantation
[9,11,12] and the challenges and opportunities of devel-
oping human Treg therapy recently discussed [13].
Despite the growing importance of this subset in T
cell immunobiology, there has been no systematic
study to date comparing the Treg contents of the
main 2 types of HSCTs, that is, BM and PBSC.We re-
port herein that Treg frequencies are significantly
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and that most Tregs from PBSCTs are CD62Llo.MATERIAL AND METHODS
Biologic Samples
BMTs (n5 29) or PBSCTs (n5 55) were har-
vested consecutively by Etablissement Franc¸ais du
Sang de Normandie (Bois-Guillaume, France) from
healthy donors who gave informed consent. All bio-
logic samples used in this study were fresh (not frozen).
Flow Cytometry
FITC-, PC5-, PE-, ECD-, RD1-, or APC-Cy5-
conjugated monoclonal antibodies (mAbs) directed
to CD3, CD4, CD8, CD25, CD19, HLA-DR, CD2,
CD62L, CD45RO, CD45RA, and CD127, or
FITC-labeled Annexin V were from Beckman Coulter
(Fullerton, CA), BD PharMingen (San Diego, CA), or
eBioscience (San Diego, CA). Intracellular FoxP3
staining was performed following the manufacturer’s
protocol (eBioscience).
Flow cytometry analyses were performed on an
EPICS XL-MCL (Beckmann Coulter) using the
System II software, except Annexin V analyses per-
formed on a FACSCanto (BectonDickinson, Franklin
Lakes, NJ) using the FlowJo software (Tree Star,
Ashland, OR).
Statistical Analysis
TheMann-Whitney test was used to compare data
(Prism 4.00 software, Graph Pad, San Diego, CA),
unless otherwise mentioned.Figure 1. Reduced Treg frequencies in PBSC compared to BM trans-
plants. (A) Flow cytometry analysis of a representative PBSC transplant.
Cells were stained with RD1 anti-CD25 and ECD anti-CD4 (left), PE
anti-FoxP3 and ECD anti-CD4 (intracellular staining, center), or RD1
anti-CD25 and FITC anti-CD127 (right). Data are gated on MNC (left
and center) or CD41 T cells (right). Numbers indicate cell frequency
in the depicted region or quadrant. (B) Treg frequencies in BM
(n5 29) and PBSC (n5 55) transplants. Horizontal trait indicates me-
dian, box represents 25th and 75th percentiles, error bars depict 10th
and 90th percentiles, and dots are individual values below or above
the 10th and 90th percentiles, respectively. (C) Total CD31 T cell
numbers in BM and PBSC transplants: (mean + SEM). (D) Box plots of
the frequency of Annexin-V1 cells within CD41CD251CD127lo (Tregs)
and CD41CD252 (Tconv) subsets, in the blood of donors after G-CSF
administration (before leukapheresis) and in the PBSC transplant.
Horizontal trait indicates median, box represents 25th and 75th percen-
tiles, and error bars depicts range of values. Significant P-values #.05,
#.01, and #.001 are indicated by *, **, and ***, respectively.RESULTS AND DISCUSSION
Tregs, defined as CD41CD25hi, CD41FoxP31 or
CD41CD251CD127lo can be readily detected in
HSCTs (Figure 1A). When comparing BM and
PBSC, Treg frequencies appeared significantly lower
in the latter compared to the former (Figure 1B). For in-
stance, the median proportion of CD25hi cells among
transplants’ CD41 T cells dropped from 7.2% to
4.7% (P\.001).The frequency of PBSCCD41CD25hi
cells correlated with that of CD41FoxP31 cells (P\
.0001, not shown). The reduction was also highly statis-
tically significant whenTregs were identified as CD251
CD127lo cells because theirmedian frequencydecreased
from 9.4% to 6.8% (P\ .001).
The frequency of Tregs withinHSCTs has a major
impact on the risk ofGVHD. Inmice,manipulating the
ratio of Tregs to conventional T cells (Tconv) by Treg
depletion or addition significantly accelerates or re-
duces GVHD mortality, respectively [9]. Here, the ra-
tio of Tregs to CD41CD25- Tconv dropped bynearly 50% between BM and PBSC transplants (from
an average ratio of 0.176 0.03 to 0.096 0.01, respec-
tively).ThisTreg impoverishmentmaybe an important
Figure 2. Decrease ofCD62L1Tregs during collect of PBSC transplants.
(A) Flowcytometry analysis of Tregs fromPBSCdonor blood samples (be-
fore G-CSF, n5 19) or from BM (n5 26) or PBSC (n5 53) transplants.
Histograms (mean1 SEM) indicate the frequency of CD62L expression
on Tregs, the proportion of CD62L1 Treg and the frequency of several
phenotypic markers in CD41CD25hi Tregs. Stainings were performed us-
ing RD1 anti-CD25, ECD anti-CD4 and 1 of the following FITC-labeled
anti-CD62L, anti-CD45RO, anti-CD45RA, or anti-HLA-DR antibodies.
(B) Flow cytometry analysis of CD62L expression at the surface of
CD41CD25hi Tregs. Box plots indicate the percentageofCD25hiCD62L1
cells within the CD41 T cell gate (n5 11), in the blood of donors before
G-CSF administration, after G-CSF administration (before leukapheresis),
and in the PBSC transplant. Horizontal trait indicates median, box repre-
sents 25th and 75th percentiles, and error bars depicts range of values.
Data were compared by ANOVA. Significant P-values #.01 and #.001
are indicated by ** and ***, respectively.
432 Biol Blood Marrow Transplant 16:430-434, 2010C. Blache et al.factorgoverning theoverall alloreactivity of thegraft in-
asmuch as the total numbers of T cells infused is dra-
matically higher when using a PBSCT rather than
a BMT (Figure 1C). One explanation for the lower
PBSCTreg frequencies could be a preferential sensitiv-
ity to apoptosis. In support of this hypothesis, Annexin-
V labeling was significantly higher in Tregs. This was
not only the case when comparing Treg and Tconv
within PBSC samples, but also before leukapheresis
when analyzing donor blood after G-CSF administra-
tion (Figure 1D).
It has been suggested that CD62L1 Tregs may
have higher immunosuppressive properties in vitro
than CD62L- Tregs [14], and that only the former
might possess the capacity to control GVHD [15,16].
Nevertheless, this point remains controversial because
the 2 Treg subpopulations seems equally capable of
preventing gastritis and colitis despite possible differ-
ent migration pattern [14]. When investigating the
CD62L phenotype of Tregs, we found BM Tregs in-
distinguishable from donor blood Tregs on that basis
(Figure 2A). One of the striking findings of this study
was a dramatic loss of CD62L1Tregs within PBSCTs.
Indeed, whereas the vast majority of BM Tregs were
CD62L1 (mean6 SEM, 88.3% 6 1.5%), there was
a 2-fold reduction in the frequency of CD62L1 cell-
s among Tregs when turning to PBSCTs (45.8% 6
2.9%). Tregs can be separated into amajor CD45RO1
memory-type and minor CD45RA1 naive-type subset
(Figure 2A), in accordance with previous observations
[17]. The reduction in PBSC CD62L1 Tregs cannot
be ascribed to a selective loss of naive-type CD45RA1
Tregs, because their frequency was not different be-
tween donor blood and PBSC samples (Figure 2A).
There was even a slight increase in the frequency of na-
ive-typeTregs in BM, but this subtype remained inmi-
nor proportion compared to memory-type Tregs
(Figure 2A). Hence, Treg frequencies are diminished
within PBSCTs compared to BMTs, and half of these
Tregs display a CD62L2 phenotype.
The loss of CD62L on T cells may possibly be due
to the effect of G-CSF administration and/or to the
process of leukapheresis. To further investigate this
point, we performed a longitudinal analysis of
CD62L expression on Tregs (1) in donor blood before
G-CSF administration, (2) in donor blood after
G-CSF administration but before leukapheresis, and
(3) in the final PBSC product. The frequency of
CD62L1CD25hi cells among CD41 T cells signifi-
cantly decreased from 4.7% 6 0.4% to 3.9% 6
0.5% upon the administration of G-CSF (Figure 2B,
P\ .05), consistent with a previous report showing
that G-CSF in vivo may induce loss of CD62L on total
CD31 cells [18]. Interestingly, loss of CD62L on
Tregs could not be ascribed to the sole effect of
G-CSF because leukapheresis itself further aggravated
this phenomenon by reducing the CD62L1CD25hi
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(Figure 2B, P\ .01). The mechanisms by which leuka-
pheresis may influence CD62L shedding on Tregs
may deserve further investigation. Yet, it has been re-
ported that intracellular molecules released by cellular
stress or cell death, such as adenosine triphosphate
(ATP), may act on surface receptors notably the puri-
nergic receptor P2X7 to induce shedding of CD62L
on lymphocytes and even T cell death in mice and
humans [19,20]. Because leukapheresis is a cause of
cellular stress [21] and Tregs are more sensitive to
ATP than Tconv [22], it is possible that this mecha-
nism contributes to the low CD62L1 Treg content
of PBSC transplants.
Together, the results of this study show that Treg
frequencies are lower in PBSCTs than in BMTs and
that Tregs from PBSCTs are mostly CD62L2. Differ-
ent reports have shown that G-CSF treatment may be
associated with alterations in donor lymphocyte func-
tion and/or induction of potentially GVHD-protec-
tive lymphocytes [23-27]. From this biologic
observation, it could be expected that PBSCT is en-
dowed with a low risk of GVHD. However, several
clinical studies including meta-analyses have shown
that, for yet poorly understood reasons, the probability
of developing chronic GVHD (cGVHD) is actually
significantly increased in patients receiving PBSCTs
compared to BMTs [28-30]. The present study was de-
signed to compare the Treg content of both types of
transplants but not to analyze the risk of GVHD. In
addition to already published data [5-8], it would be in-
teresting to further evaluate the correlation between
GVHD occurrence and the type of graft (BMT versus
PBSCT) with regard to the graft Treg content. One of
the main factors that may augment the risk of GVHD
after PBSCT compared to BMT is the considerably
higher (10-fold) number of administered CD31
T cells in PBSCT. The reduced Treg content and pos-
sibly the CD62L2 phenotype of PBSCTs described
herein may represent additional factors contributing
to this higher risk of GVHD.ACKNOWLEDGMENTS
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